Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 6,901–7,000 of 15,747
Libotte, G. B., dos Anjos, L., de Almeida, R. C. C., Malta, S. M. C., & Medronho, R. D. A. (2022) · Journal of the Royal Society Interface · doi:10.1098/rsif.2022.0275 · Cited by 6
“Of note, the recommended inter-dose interval for Pfizer-BioNTech vaccines is 21–28 days [43].”
BackgroundResultEffects of various mRNA-LNP vaccine doses on neuroinflammation in BALB/c mice
Kirshina, A., Kazakova, A., Kolosova, E., Имашева, Е. А., Vasileva, O., Zaborova, O. V., Terenin, I. M., Muslimov, A., & Reshetnikov, V. V. (2022) · Вестник Российского государственного медицинского университета · doi:10.24075/brsmu.2022.068 · Cited by 19
Lei, J., Qi, S., Yu, X., Gao, X., Yang, K., Zhang, X., Cheng, M., Bai, B., Feng, Y., Lu, M., et al. (2024) · Angewandte Chemie · doi:10.1002/ange.202318515 · Cited by 16
Lu, W., Zeng, S., Yao, Y., Luo, Y., & Ruan, T. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1338208 · Cited by 12
“The vaccination regimen currently comprises complete vaccination (two doses), and the booster vaccination (three doses) in children (14, 15).”
Broad protection and respiratory immunity of dual mRNA vaccination against SARS-CoV-2 variants
Hajnik, R. L., Plante, J. A., Bonam, S. R., Rafael, G. H., Liang, Y., Hazell, N. C., Walker, J. L., Reyna, R. A., Walker, D. H., Alameh, M., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00957-2 · Cited by 12
Damodharan, K., Arumugam, G. S., Ganesan, S., Doble, M., & Thennarasu, S. (2021) · RSC Advances · doi:10.1039/d0ra09668g · Cited by 14
A Molecular View of Lipid Nanoparticles: Insights into their Morphology and Structural Plasticity
Porte, S., Vadhana, V., & Sengupta, D. (2025) · Small · doi:10.1002/smll.202505404 · Cited by 17
Hyun, H., Choi, M.-J., Nham, E., Seong, H., Yoon, J. G., Noh, J.-Y., Cheong, H. J., Kim, W. J., Yoon, S.-K., Park, S.-J., et al. (2023) · Vaccines · doi:10.3390/vaccines11081320 · Cited by 10
“The frequency and intensity of solicited adverse events were lower than those after the primary second dose vaccination [22,23].”
BackgroundDouxfils, J., Gillot, C., Gottal, É. D., Vandervinne, S., Bayart, J., Dogné, J., & Favresse, J. (2021) · Vaccines · doi:10.3390/vaccines9080907 · Cited by 11
Hosseini‐Motlagh, S., Samani, M. R. G., & Farokhnejad, P. (2023) · International Journal of Production Research · doi:10.1080/00207543.2023.2254394 · Cited by 12
“Previous epidemiological studies have demonstrated the efficacy of COVID-19 vaccinations in reducing virus transmission, severe infections, hospitalisations, and mortality (Dagan et al. 2021; Polack et al. 2020; Voysey et al. 2021).”
CALMS: Modelling the long-term health and economic impact of Covid-19 using agent-based simulation
Mintram, K. S., Anagnostou, A., Anokye, N., Okine, E., Groen, D., Saha, A., Abubakar, N. T., Islam, T., Daroge, H., Ghorbani, M., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0272664 · Cited by 14
Sodium Toxicity in the Nutritional Epidemiology and Nutritional Immunology of COVID-19
Brown, R. B. (2021) · Medicina · doi:10.3390/medicina57080739 · Cited by 11
Development of a patient decision aid for COVID-19 vaccination with the Comirnaty vaccine
Vincent, Y.-M., Frachon, A., Allaire, A., Boussageon, R., Pouchain, D., Ferrat, É., & Rat, C. (2021) · Family Practice · doi:10.1093/fampra/cmab156 · Cited by 11
COVID-19 vaccines in high-risk ethnic groups
D’Souza, R., & Wolfe, I. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00624-3 · Cited by 11
Shoulder Injury Related to Vaccine Administration and a Growing Challenge: A Focused Review
Pettyjohn, E. W., Clugston, J. R., & Zaremski, J. L. (2022) · Current Sports Medicine Reports · doi:10.1249/jsr.0000000000000939 · Cited by 11
Papadimitriou, I., Bakirtzi, K., Sotiriou, E., et al. (2021) · Clinical and Experimental Dermatology · doi:10.1111/ced.14856 · Cited by 11
Yau, K., Tam, P. Y., Chan, C. T., Hu, Q., Qi, F., Abe, K. T., Kurtesi, A., Jiang, Y., Estrada-Codecido, J., Brown, T., et al. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000328 · Cited by 11
Durable immune responses after BNT162b2 vaccination in home-dwelling old adults
Hansen, L., Brokstad, K. A., Bansal, A., Zhou, F., Bredholt, G., Onyango, T. B., Sandnes, H. H., Elyanow, R., Madsen, A., Trieu, M.-C., et al. (2023) · Vaccine X · doi:10.1016/j.jvacx.2023.100262 · Cited by 15
“The rapid development and implementation of COVID-19 vaccines have changed the trajectory of the COVID-19 pandemic.”
InfluentialBuilding the U.S. COVID-19 vaccine effectiveness program: Past successes and future directions
Link‐Gelles, R., Britton, A., & Fleming-Dutra, K. E. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.12.002 · Cited by 15
Vaccines and nephrotic syndrome: efficacy and safety
Angeletti, A., Lugani, F., Porta, E. L., Verrina, E. E., Caridi, G., & Ghiggeri, G. M. (2022) · Pediatric Nephrology · doi:10.1007/s00467-022-05835-4 · Cited by 15
Quantitative serological evaluation as a valuable tool in the COVID-19 vaccination campaign
Ferrari, D., Mangia, A., Spanò, S. M., Zaffarano, L., Viganò, M., Resta, C. D., Locatelli, M., Ciceri, F., & Vecchi, E. D. (2021) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2021-0364 · Cited by 11
Weng, Y., Lu, D., Bollyky, J., Jain, V., Desai, M., Lindan, C., Boothroyd, D. B., Judson, T. J., Doernberg, S. B., Holubar, M. K., et al. (2021) · Vaccines · doi:10.3390/vaccines9121406 · Cited by 13
Collaborative, T. O., Zheng, B., Campbell, J., Carr, E. J., Tazare, J., Nab, L., Mahalingasivam, V., Mehrkar, A., Santhakumaran, S., Steenkamp, R. D., et al. (2022) · medRxiv · doi:10.1101/2022.12.02.22283049 · Cited by 12
General sites of nanoparticle biodistribution as a novel opportunity for nanomedicine
Fleischmann, D., & Göpferich, A. M. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.05.027 · Cited by 14
RNA Vaccines against Infectious Diseases: Vital Progress with Room for Improvement
Abdelzaher, H. M., Gabr, A. S., Saleh, B. M., Gawad, R. M. A., Nour, A. A., & Abdelnaser, A. (2021) · Vaccines · doi:10.3390/vaccines9111211 · Cited by 13
“Adverse events for this vaccine ranged between injection site reactions, fatigue, headaches, and fevers (reported in 27% of patients) [3].”
BackgroundSu, N., Wiefels, C., Klein, R., et al. (2022) · Journal of medical imaging and radiation sciences · doi:10.1016/j.jmir.2022.01.004 · Cited by 11
“In term of patient’s age, we found that younger vaccinated patients were more likely to develop FDG-avid axillary lymph node, which mirrors the clinical findings published in the Pfizer-BioNTech vaccine trial [9] .”
Recent update on future therapeutic strategies for COVID-19 vaccination with omicron variant
Ellakwa, D. E., Elsheikh-Hassan, A. F., Ellakwa, T. E., & Abdelmalek, M. A. (2024) · Human Gene · doi:10.1016/j.humgen.2024.201281 · Cited by 11
Siles, N., Schuler, M., Maguire, C. P., Amengor, D., Nguyen, A. W., Wilen, R. E., Rogers, J. E., Bazzi, S. A., Caslin, B., DiPasquale, C., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-00828-4 · Cited by 12
Ripabelli, G., Sammarco, M. L., D’Amico, A., Dona, R. D., Iafigliola, M., Parente, A., Samprati, N., Santagata, A., Adesso, C., Natale, A., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2126668 · Cited by 12
“3%).(12,27) Data on lymphadenopathy in pediatric population are limited but, in the FDA authorization document, swollen lymph nodes were reported after vaccination in recipients aged 5 through 11 years, which were followed for safety for at least 2 months after the second dose.”
BackgroundMethodAn mRNA vaccine encoding proteasome-targeted antigen enhances CD8+ T cell immunity
Ling, J., Chen, H., Huang, M., Wang, J., & Du, X. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.02.074 · Cited by 13
Johnson, S., Mielke, N., Mathew, T. A., Maine, G. N., Chen, N., & Bahl, A. (2022) · Journal of the American College of Emergency Physicians Open · doi:10.1002/emp2.12793 · Cited by 11
“19 With the goal of reaching an unbiased tree, the procedure repeats until 2 stopping criteria: (1) 5% level of significance and (2) minimum sample size of 900, 300, 100, and 100 for all UV patients, UV hospitalized patients, all FV patients, and FV hospitalized patients, respectively, at terminal nodes.”
Tu, Z., Yu, Q., Wu, R., Meng, M., Guo, X., Chen, J., Tang, Z., Hao, K., Tian, H., & Chen, X. (2024) · Chemistry of Materials · doi:10.1021/acs.chemmater.3c03219 · Cited by 11
Yuniar, C. T., Pratiwi, B., Ihsan, A. F., Laksono, B. T., Risfayanti, I., Fathadina, A., Jeong, Y., & Kim, E. Y. (2022) · Vaccines · doi:10.3390/vaccines10020313 · Cited by 16
“Eighteen studies using vaccines with adjuvants: AlOH3/Algel-IMDG in 21 studies [18–20,27–31,35,45,48,51, 52,55–57,59,64,66,68,70], Matrix-M1 in three studies [21,63,74], AS03/CpG + Alum in one study [25], Af03/AS03 in one study [36], and MF59 in one study [42].”
BackgroundMethodOhkubo, Y., Ohmura, S., Ishihara, R., & Miyamoto, T. (2022) · Modern Rheumatology Case Reports · doi:10.1093/mrcr/rxac085 · Cited by 11
“Viral mRNA is administered into human cells in the epithelium encapsulated in lipid nanoparticles which undergoes cellular translation to form the target spike protein and promote antibody formation [7].”
BackgroundChallenges and Recent Advancements in COVID-19 Vaccines
Wang, S.-C., Rai, C.-I., & Chen, Y. (2023) · Microorganisms · doi:10.3390/microorganisms11030787 · Cited by 11
Guo, Y., Cao, X., Yang, H.-T., Zhou, M., & Yu, B. (2023) · Journal of Global Health · doi:10.7189/jogh.13.06008 · Cited by 13
Laub, O., Leipold, G., Toncheva, A. A., Peterhoff, D., Einhauser, S., Neckermann, P., Borchers, N. S., Santos-Valente, E., Kheiroddin, P., Buntrock‐Döpke, H., et al. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.678937 · Cited by 16
“When vaccination for SARS-CoV-2 was first administered to adults, stronger systemic vaccination reactions to the vaccine were reported in younger individuals (7).”
BackgroundTong, T., D’Addabbo, A., Xu, J., Chawla, H., Nguyen, A., Ochoa, P., Crispin, M., & Binley, J. Μ. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011452 · Cited by 12
Michels, C. A., Perrier, D., Kunadhasan, J., Clark, E., Gehrett, J., Gehrett, B., Kwiatek, K., Adams, S., Chandler, R. W., Stagno, L., et al. (2023) · International Journal of Vaccine Theory Practice and Research · doi:10.56098/ijvtpr.v3i1.85 · Cited by 13
Addressing misclassification bias in vaccine effectiveness studies with an application to Covid-19
Eusebi, P., Speybroeck, N., Hartnack, S., Stærk‐Østergaard, J., Denwood, M. J., & Kostoulas, P. (2023) · BMC Medical Research Methodology · doi:10.1186/s12874-023-01853-4 · Cited by 11
The path to find an HIV vaccine
Gray, G., & Corey, L. (2021) · Journal of the International AIDS Society · doi:10.1002/jia2.25749 · Cited by 11
“These findings stood in contrast to traditional vaccine development, which relies on eliciting high levels of broadly neutralizing antibodies as the major mechanism of protection most recently exemplified by the high rate of success of COVID-19 vaccines [4-7].”
ResultAl-Ghuraibi, M., Dighriri, I. M., Elrggal, M. E., & Obaid, N. A. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1026252 · Cited by 12
“(23), for example, concluded that a two-dose regimen of the Pfizer BioNTech COVID-19 vaccine (BNT162b2) was 95% effective in preventing COVID-19 in adults aged 16 and older (23).”
BackgroundAnalyzing the U.S. Post-marketing safety surveillance of COVID-19 vaccines
Albalawi, O. M., Alomran, M. I., Alsagri, G. M., Althunian, T. A., & Alshammari, T. M. (2021) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2021.12.008 · Cited by 12
New insights for the development of efficient DNA vaccines
Berger, S., Zeyn, Y., Wagner, E., & Bros, M. (2024) · Microbial Biotechnology · doi:10.1111/1751-7915.70053 · Cited by 17
Rahmani, A., Dini, G., Orsi, A., Sticchi, L., Bruzzone, B. M., Montecucco, A., Pellegrini, L., Manca, A., Domnich, A., Battistini, A., et al. (2021) · Vaccines · doi:10.3390/vaccines9111269 · Cited by 12
“Data from clinical trials of this vaccine have shown that participants reported local and systemic reactions, such as injection site pain, fatigue, and headache; greater reactogenicity was reported following the second dose and among the young adult age group [13].”
BackgroundMethodResultInfluentialLeón, T. M., Vargo, J., Pan, E., Jain, S., & Shete, P. B. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab415 · Cited by 12
Is a single COVID-19 vaccine dose enough in convalescents ?
Focosi, D., Baj, A., & Maggi, F. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1917238 · Cited by 13
Kim, B., Park, Y., Kim, E., et al. (2021) · Clinical Imaging · doi:10.1016/j.clinimag.2021.05.031 · Cited by 11
Tan, S. T., Rodríguez-Barraquer, I., Kwan, A. T., Blumberg, S., Park, H. J., Hutchinson, J., Leidner, D., Lewnard, J. A., Sears, D., & Lo, N. C. (2025) · Nature Communications · doi:10.1038/s41467-024-55029-9 · Cited by 14
Immune Response Related to Lymphadenopathy Post COVID-19 Vaccination
Ho, T., Shen, D. H.-Y., Chang, C.-C., Chan, H.-P., Chuang, K., Yuan, C., Chen, C.-N., Yang, M., & Tyan, Y. (2023) · Vaccines · doi:10.3390/vaccines11030696 · Cited by 12
Ang, M. J. Y., Balakrishnan, N., Bae, K. H., Wang, Q., Wu, Z., Wang, Y., Zhang, P., Seow, B. Y. L., Liu, X., & Yang, Y. Y. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113907 · Cited by 13
Gurjar, P., Karuvantevida, N. S., Rzhepakovsky, I. V., Khan, A. A., & Khandia, R. (2023) · Vaccines · doi:10.3390/vaccines11020487 · Cited by 11
Harnessing the Loop: The Perspective of Circular RNA in Modern Therapeutics
Zhao, Y.-Y., Zhu, F.-M., Zhang, Y.-J., & Wei, H. Y. (2025) · Vaccines · doi:10.3390/vaccines13080821 · Cited by 20
SARS-CoV-2 Infection Drives a Glycan Switch of Peripheral T Cells at Diagnosis
Alves, I., Vicente, M. M., Gaifem, J., Fernandes, Â., Dias, A. M., Rodrigues, C. S., Oliveira, J. C., Seixas, N., Malheiro, L., Abreu, M. A., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100131 · Cited by 11
Filippatos, F., Tatsi, E., Dellis, C., Dessypris, N., Syriopoulou, V., & Michos, A. G. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1985356 · Cited by 13
“BNT162b2 mRNA COVID-19 vaccine (BioNTech, Fosun Pharma, Pfizer) was one of the first vaccines to be licensed worldwide and was characterized by high immunogenicity and efficacy rate.(3) A recent observational study from Israel with nearly 570000 BNT162b2 mRNA COVID-19 vaccinated participants demonstrate a highly effec…”
BackgroundSolís-Andrade, K. I., González‐Ortega, O., Govea‐Alonso, D. O., Comas‐García, M., & Rosales‐Mendoza, S. (2022) · Vaccines · doi:10.3390/vaccines10101759 · Cited by 10
Progress in antisenescence biomaterials for improved osteoarthritis therapy
Ge, Y.-S., Ding, J.-Y., Shen, J., Meng, T.-T., Huang, C.-M., Li, W.-Y., Zhao, M.-J., Yin, J.-L., Zhai, Y.-Q., Wang, X., et al. (2025) · Acta Biomaterialia · doi:10.1016/j.actbio.2025.08.044 · Cited by 15
Ferdous, N., Reza, M. N., Hossain, M. U., Mahmud, S., Napis, S., Chowdhury, K., & Mohiuddin, A. K. M. (2023) · PLoS ONE · doi:10.1371/journal.pone.0287179 · Cited by 15
Discovering COVID-19 state sustainable policies for mitigating and ending the pandemic
Takefuji, Y. (2022) · Cities · doi:10.1016/j.cities.2022.103865 · Cited by 11
“Although the efficacy of vaccines against COVID-19 has been published in many papers (Nasreen et al., 2022; Olson et al., 2022; Polack et al., 2020; Tang et al., 2021; Tregoning et al., 2021; Wood, 2022), real-world results show that the claims have not been fulfilled yet.”
van der Boom, M. D. X., van Eekeren, R., & van Hunsel, F. P. A. M. (2023) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5610 · Cited by 11
Yin, F., Crooks, A. T., & Yin, L. (2022) · Computers Environment and Urban Systems · doi:10.1016/j.compenvurbsys.2022.101887 · Cited by 12
“As one of the most important measures for preventing communicable infectious diseases (Andre et al., 2008), vaccination plays an important role to protect people against diseases and has been shown to save lives (Polack et al., 2020).”
BackgroundInshasi, J. S. S., Alroughani, R., Al-Asmi, A. R., Al-Khabouri, J., Alsalti, A., Boshra, A., Canibaño, B., Deleu, D., Ahmed, S. F., Shatila, A. O., et al. (2021) · Neurology and Therapy · doi:10.1007/s40120-021-00260-5 · Cited by 11
Biodegradable Polyester Nanoparticle Vaccines Deliver Self‐Amplifying mRNA in Mice at Low Doses
Wilson, D. R., Tzeng, S. Y., Rui, Y., Neshat, S. Y., Conge, M., Luly, K. M., Wang, E. B., Firestone, J. L., McAuliffe, J., Maruggi, G., et al. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202200219 · Cited by 13
Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy
Brown, R. B. (2022) · Dialogues in Health · doi:10.1016/j.dialog.2022.100074 · Cited by 11
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infectionwith at least one clinical symptom [31,32].”
Shaharyar, M. A., Bhowmik, R., Al-Abbasi, F. A., AlGhamdi, S. A., Alghamdi, A. M., Sarkar, A., Kazmi, I. A., & Karmakar, S. (2023) · Vaccines · doi:10.3390/vaccines11020241 · Cited by 12
“There has been successful double-dosing of mRNA vaccines, with either a 3-week or 4-weeks gap [200,208].”
Lin, W., Yip, A. C. L., Evangelista, L. K. M., Wong, R. C.-C., Tan, H. C., Lim, T. W., & Singh, D. (2022) · Pacing and Clinical Electrophysiology · doi:10.1111/pace.14486 · Cited by 11
Pacheco, T. J. A., da Silva, V. C. M., & de Souza, D. G. (2020) · Research Society and Development · doi:10.33448/rsd-v9i12.11123 · Cited by 11
Baldwin, J., Noorali, S., & Vaseashta, A. (2023) · COVID · doi:10.3390/covid3090089 · Cited by 14
Progress Towards a Therapeutic HIV DNA Vaccine
Munson, P. V. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2059467 · Cited by 12
“The recent meteoric rise of mRNAbased vaccines has been a boon to the nucleic acid vaccine field [176,177].”
BackgroundMaterials‐based vaccines for infectious diseases
Yang, B., & Wang, H. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1824 · Cited by 12
Milito, C., Cinetto, F., Garzi, G., Palladino, A., Puca, M., Brambilla, E., Vitis, C. D., Costanzo, G. A. M. L., Scarpa, R., Punziano, A., et al. (2022) · Journal of Clinical Immunology · doi:10.1007/s10875-022-01402-6 · Cited by 10
Suphanchaimat, R., Nittayasoot, N., Thammawijaya, P., Teekasap, P., & Ungchusak, K. (2021) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s318012 · Cited by 12
Damluji, A. A., Christenson, R. H., & deFilippi, C. R. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019506 · Cited by 9
Daly, O. M., Mahiny, A. J., Majeski, S., McClintock, K., Reichert, J., Boros, G., Szabó, G. T., Reinholz, J., Schreiner, P., Reid, S., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11061735 · Cited by 12
“The screening included alpha-globin 5′UTR and AES and mtRNR1 3′UTR that were previously used in the BioNTech-Pfizer COVID-19 vaccine and are known to contain motifs that increase the translation and stability of mRNA [26,27].”
BackgroundInfluentialBayraktutan, H., Symonds, P., Brentville, V. A., Moloney, C., Galley, C., Bennett, C. L., Mata, Á., Durrant, L. G., Alexander, C., & Gurnani, P. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122647 · Cited by 15
Vaccines for Respiratory Viruses—COVID and Beyond
Rajanala, K., & Upadhyay, A. (2024) · Vaccines · doi:10.3390/vaccines12080936 · Cited by 13
“The Pfizer-BioNTech’s (BNT162b2) [23,24] and Moderna’s (mRNA-1273) [25,26] vaccines, which utilized mRNA technology, were among the first to receive Emergency Use Authorization (EUA) from the U.S. FDA in December 2020.”
BackgroundMahrhofer, M., Weitgasser, L., & Schoeller, T. (2021) · Aesthetic Surgery Journal Open Forum · doi:10.1093/asjof/ojab035 · Cited by 10
A Brief Review on Medicinal Plants-At-Arms against COVID-19
Srivastava, S., He, F., Huang, Y., Niu, M., Adholeya, A., & Peng, W. K. (2023) · Interdisciplinary Perspectives on Infectious Diseases · doi:10.1155/2023/7598307 · Cited by 11
Hoehn, S. J., Krul, S. E., Skory, B. J., & Crespo‐Hernández, C. E. (2021) · Chemistry - A European Journal · doi:10.1002/chem.202103667 · Cited by 9
Altawalah, H., Alfouzan, W. A., Al-Fadalah, T., & Ezzikouri, S. (2021) · Diagnostics · doi:10.3390/diagnostics11112110 · Cited by 11
“COVID-19 vaccines reduce severe disease and death from SARS-CoV2 infection [13,14] but breakthrough cases occur [15,16].”
BackgroundSARS-CoV-2: Pathogenic Mechanisms and Host Immune Response
Yasmin, H., Saha, S., Butt, M. T., Modi, R. K., George, A. J. T., & Kishore, U. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-67452-6_6 · Cited by 10
Bilgin, H., Marku, M., Yılmaz, S. S., Yağcı, A., Sili, U., Can, B., Sarınoğlu, R. C., Mülazımoğlu, L., Haklar, G., Şïrïkçï, Ö., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.03.001 · Cited by 13
“Trials with existing vaccines have shown varying degrees of humoral and cellular immune responses against SARS-CoV-2 [10-16].”
BackgroundLanglete, P., Tesli, M., Veneti, L., Starrfelt, J., Elstrøm, P., & Meijerink, H. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.05.022 · Cited by 12
“In 50 general, these vaccines have shown high efficacy in clinical trials and good effectiveness from observational 51 studies [1-7].”
Morishita, T., Sakai, A., & Matsunami, H. (2022) · Transplantation · doi:10.1097/tp.0000000000004043 · Cited by 11
Lonati, P. A., Bodio, C., Scavone, M., Martini, G., Pesce, E., Bandera, A., Lombardi, A., Gerosa, M., Franceschini, F., Tincani, A., et al. (2022) · RMD Open · doi:10.1136/rmdopen-2021-001902 · Cited by 10
“Severe adverse side effects as defined by Polack et al 17 or any clinical manifestations potentially correlated with vaccination were also recorded for all the investigated patients or subjects (online supplemental table).”
BackgroundCOVID-19 Vaccination Policies: Ethical Issues and Responsibility
Marrone, M., Buongiorno, L., Stellacci, A., Cazzato, G., Stefanizzi, P., & Tafuri, S. (2022) · Vaccines · doi:10.3390/vaccines10101602 · Cited by 10
Hutchison, J. M., Capone, R. F., Luu, D. D., et al. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100940 · Cited by 10
“(2021) 297(2) 100940 with previous SARS-CoV-1E (40) and preliminary S2-E (17) channel measurements in terms of current amplitudes, sodium cation selectivity, and open probabilities (Fig.”
Yu, Q., Jiang, W., Chen, N., Li, J., Wang, X., Li, M., Wang, D., & Jiang, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.875637 · Cited by 10
Vlachakis, P. K., Theofilis, P., Σουλαϊδόπουλος, Σ., Lazarou, E., Tsioufis, K. P., & Lazaros, G. A. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s261119 · Cited by 12
What are the challenges faced by COVID-19 vaccines?
Abdalla, M., El‐Arabey, A. A., & Jiang, X. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2008245 · Cited by 10
“S (Johnson & Johnson) and ChAdOx1 (AstraZeneca); lipid nanoparticles (LNPs).”
BackgroundGraceffa, D., Sperati, F., Bonifati, C., Spoletini, G., Lora, V., Pimpinelli, F., Pontone, M., Pellini, R., Bella, O. D., Morrone, A., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.961904 · Cited by 13
“The BNT162b2 vaccine is highly effective and safe, as demonstrated in phase 3 clinical trials, reaching a clinical efficacy of 95% in preventing severe forms of COVID-19 (26).”
BackgroundWalton, M., Tomkies, R., Teunissen, T., Lumley, T., & Hanlon, T. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2022.12.012 · Cited by 11
“Our finding of no increased risk across different ethnic groups including Māori and Pacific peoples, can provide reassurance to the public and policy makers on the safety of the vaccine, especially as these groups were not represented in the BNT162b2 vaccine phase III clinical trials [10].”
BackgroundLipid Nanoparticle: Beyond Delivery Vehicle—Unveiling Its Immunological Adjuvant Potential
Amor, N. P., Guo, K., Zhang, S., Xia, J., Yang, Y., & Lin, A. (2025) · The FASEB Journal · doi:10.1096/fj.202500622r · Cited by 13
“This has propelled LNP to the forefront of the mRNA vaccine field, and most noticeable are the LNP-formulated mRNA vaccines for COVID-19 from BioNTech/Pfizer and Moderna [24, 25].”
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.